| S1: |
It’s Thyroid Cancer Awareness Month |
| S2: |
Blueprint Medicines stands with thyroid cancer patients |
| S3: |
We’re spreading awareness about thyroid cancer |
| S4: |
Join us in raising awareness this Thyroid Cancer Awareness Month |
| S5: |
How are you supporting Thyroid Cancer Awareness Month? |
|
|
|
[From: <Rep Name> (REPNAME@blueprintmedicines.com)]
[Sent: <MM/DD/YYYY HH:MM AM/PM>]
[To: <Last Name, First Name>]
|
|
|
[pick list]
[Dear]
[Hello]
[pick list]
[Dr. Last Name],
[First Name],
[First Name Last Name],
|
|
[Customize the text here with your own message to the healthcare provider in alignment with FDM. You may only send a 200-character message in alignment with FDM.]
|
|
September is Thyroid Cancer Awareness Month. To help spread awareness, I’d like to share some important statistics on thyroid cancer and resources for your patients with advanced thyroid cancer.
|
| • |
Thyroid cancer is the 12th most common type of cancer in the U.S.1 |
| • |
There will be an estimated 43,800 new cases of thyroid cancer diagnosed in 2022 in the U.S.1 |
| • |
RET is one of several key biomarkers known to cause certain advanced thyroid cancers, along with BRAF, NTRK, ALK, and more2-5
| – |
~10%-20% of patients with papillary thyroid cancer are RET+4,6 |
| – |
~50% of patients with somatic medullary thyroid cancer are RET+7-9 |
| – |
~100% of patients with germline medullary thyroid cancer are RET+7-9 |
|
|
|
ALK=anaplastic lymphoma kinase; BRAF=B-Raf proto-oncogene; NTRK=neurotrophic tyrosine receptor kinase; RET=rearranged during transfection.
|
|
|
|
|
I would be interested in learning more about your practice and how you are supporting Thyroid Cancer Awareness Month. Would you be available to set up a quick [pick list]
[falsemeetingtruecalltruevideo chat]?
|
[pick list]
[Sincerely],
[Best],
|
|
[Rep photo]
|
[pick list]
[Rep name]
[Rep title]
Blueprint Medicines
[Rep phone number]
[Rep email address]
|
|
|
References: 1. National Cancer Institute. Cancer stat facts: thyroid cancer. https://seer.cancer.gov/statfacts/html/thyro.html. Accessed June 21, 2022. 2. Lee YC, Chen JY, Huang CJ, Chen HS, Yang AH, Hang JF. Detection of NTRK1/3 rearrangements in papillary thyroid carcinoma using immunohistochemistry, fluorescent in situ hybridization, and next-generation sequencing. Endocr Pathol. 2020;31(4):348-358. 3. Panebianco F, Nikitski AV, Nikiforova MN, et al. Characterization of thyroid cancer driven by known and novel ALK fusions. Endocr Relat Cancer. 2019;26(11):803-814. 4. Drilon A, Hu ZI, Lai GGY, Tan DSW. Targeting RET-driven cancers: lessons from evolving preclinical and clinical landscapes. Nat Rev Clin Oncol. 2018;15(3):151-167. 5. Xing M, Alzahrani A, Carson K, et al. Association between BRAFV600E mutation and recurrence of papillary thyroid cancer. J Clin Oncol. 2015;33(1):42-50. 6. Kato S, Subbiah V, Marchlik E, Elkin SK, Carter JL, Kurzrock R. RET aberrations in diverse cancers: next-generation sequencing of 4,871 patients. Clin Cancer Res. 2017;23(8):1988-1997. 7. Priya SR, Dravid CS, Digumarti R, Dandekar M. Targeted therapy for medullary thyroid cancer: a review. Front Oncol. 2017;7:238. 8. Subbiah V, Gainor JF, Rahal R. Precision targeted therapy with BLU-667 for RET-driven cancers. Cancer Discov. 2018;8(7):836-849. 9. Krampitz GW, Norton JA. RET gene mutations (genotype and phenotype) of multiple endocrine neoplasia type 2 and familial medullary thyroid carcinoma. Cancer. 2014;120(13):1920-1931.
|
|
|
|
|
